MARTINI, ELISABETTA
 Distribuzione geografica
Continente #
NA - Nord America 3.959
EU - Europa 2.397
AS - Asia 1.221
SA - Sud America 153
Continente sconosciuto - Info sul continente non disponibili 47
AF - Africa 40
OC - Oceania 23
Totale 7.840
Nazione #
US - Stati Uniti d'America 3.880
RU - Federazione Russa 705
PL - Polonia 452
IT - Italia 425
SG - Singapore 327
CN - Cina 262
HK - Hong Kong 215
SE - Svezia 203
IE - Irlanda 169
VN - Vietnam 142
BR - Brasile 121
DE - Germania 100
KR - Corea 90
UA - Ucraina 85
FR - Francia 70
FI - Finlandia 65
GB - Regno Unito 58
IN - India 58
CA - Canada 52
JP - Giappone 25
AU - Australia 23
JO - Giordania 21
TR - Turchia 18
BE - Belgio 16
BD - Bangladesh 12
NL - Olanda 12
AR - Argentina 11
CI - Costa d'Avorio 10
MX - Messico 10
NG - Nigeria 9
RO - Romania 9
VE - Venezuela 9
IQ - Iraq 8
ID - Indonesia 7
PH - Filippine 6
PK - Pakistan 6
CH - Svizzera 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
ES - Italia 5
JM - Giamaica 5
ZA - Sudafrica 5
CO - Colombia 4
SC - Seychelles 4
HU - Ungheria 3
LB - Libano 3
LT - Lituania 3
MA - Marocco 3
MY - Malesia 3
SA - Arabia Saudita 3
SN - Senegal 3
AT - Austria 2
BG - Bulgaria 2
DZ - Algeria 2
EU - Europa 2
HN - Honduras 2
KZ - Kazakistan 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PR - Porto Rico 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
CL - Cile 1
CR - Costa Rica 1
EG - Egitto 1
GT - Guatemala 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LY - Libia 1
MK - Macedonia 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VI - Stati Uniti Isole Vergini 1
Totale 7.795
Città #
Santa Clara 840
Ashburn 488
Warsaw 449
Fairfield 304
Chandler 253
Singapore 238
Hong Kong 179
Dublin 168
Jacksonville 133
San Jose 127
Woodbridge 126
Seattle 116
Cambridge 115
Wilmington 99
Ann Arbor 94
Houston 93
Seoul 88
Beijing 73
Milan 72
Council Bluffs 59
Los Angeles 58
Rome 53
Buffalo 50
The Dalles 43
Boston 42
Princeton 42
Ho Chi Minh City 41
Mumbai 37
Lauterbourg 36
Altamura 34
Dallas 34
Hanoi 31
Munich 31
Phoenix 31
Lawrence 29
New York 27
Paris 27
Boardman 26
Hefei 23
Melbourne 23
Tokyo 23
Falls Church 19
Shanghai 19
Florence 17
Brussels 16
Moscow 16
Montreal 15
Medford 12
Turku 12
Bologna 11
San Diego 11
Abidjan 10
Dearborn 10
Izmir 10
London 10
Toronto 10
Abuja 9
Chicago 9
Denver 9
Helsinki 9
Hillsboro 9
Kent 9
Naples 9
San Francisco 9
São Paulo 9
Turin 9
Verona 9
Brooklyn 8
Columbus 8
Dong Ket 8
Figino 8
Haiphong 8
Tianjin 8
Venice 8
Amsterdam 7
Bari 7
Da Nang 7
Palermo 7
Brescia 6
Frankfurt Am Main 6
Norwalk 6
Orem 6
Ankara 5
Kochi 5
Miano 5
Washington 5
Auburn Hills 4
Belo Horizonte 4
Biên Hòa 4
Chennai 4
Curitiba 4
Edinburgh 4
Frankfurt am Main 4
Genoa 4
Jakarta 4
Piscataway 4
Poplar 4
Rio de Janeiro 4
West Jordan 4
Yubileyny 4
Totale 5.336
Nome #
4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs 421
Design, synthesis and binding affinity of new nicotinic ligands 354
Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition-enhancers 318
DESIGN, SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL EVALUATION OF RIGID ANALOGUES OF THE NICOTINIC AGONIST 1,1-DIMETHYL-4-PHENYLPIPERAZINIUM IODIDE (DMPP) 298
MOLECULAR MODULATION OF MUSCARINIC ANTAGONISTS. SYNTHESIS AND AFFINITY PROFILE OF 2,2-DIPHENYL-2-ETHYLTHIO-ACETIC ACID ESTERS DESIGNED TO PROBE THE BINDING SITE CAVITY 267
Design, synthesis and preliminary biological evaluation of new isoform-selective f-current blockers. 248
Central Nicotinic receptors: structure, function, ligands, and therapeutic potential 220
Design, synthesis and preliminary biological evaluation of zatebradine analogues as potential blockers of the hyperpolarization-activated current 219
2-PYRROLIDINONE MOIETY IS NOT CRITICAL FOR THE COGNITION ENHANCING ACTIVITY OF PIRACETAM-LIKE DRUGS 217
Antagonisti muscarinici a struttura 1,3-ossatiolano-2-pirrolidinica 217
Design, Synthesis, and Preliminary Pharmacological Evaluation of New Quinoline Derivatives as Nicotinic Ligands 216
SYNTHESIS, AFFINITY PROFILE AND FUNCTIONAL ACTIVITY OF MUSCARINIC ANTAGONISTS WITH A 1-METHYL-2-(2,2-ALKYLARYL-1,3-OXATHIOLAN-5-YL)PYRROLIDINE STRUCTURE 214
COGNITION-ENHANCING DRUGS IN MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD): AN UPDATE[1] 210
Highly chiral muscarinic ligands: the discovery of (2S,2'R,3'S,5'R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M2 partial agonist. 209
Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition-enhancers. 207
Design, synthesis and pharmacological evaluation of some frozen-analogues of DMPP 190
Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers 187
Design of novel nicotinic ligands through 3D database searching 183
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators. 180
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators 174
Modulazione molecolare di antagonisti muscarinici. Sintesi e valutazione farmacologica preliminare di esteri amminoalchil piperazinici e piperidinici dell'acido 2,2-difenil-2-etiltioacetico 174
[35S]GTPgammaS binding studies of amphiphilic drugs-activated Gi proteins: A caveat 171
Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent 167
Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs 157
Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs 155
Synthesis and Biological Evaluation of 3,7-Diazabicyclo[4.3.0]2 nonan-8-ones as Potential Nootropic and Analgesic Drugs 153
Synthesis, Affinity Profile and Functional Activity of Potent Chiral Muscarinic Antagonists with a Pyrrolidinylfuran Structure 153
Sintesi e valutazione farmacologica di derivati furanici e tetraidrofuranici a potenziale azione muscarinica 151
Design, synthesis and preliminary pharmacological evaluation of 1,4-diaminobenzenes and 1,4-diaminocyclohexanes as cognition modulators 151
DM232 and DM235, two potent cognition-enhancers, increase NO levels in rat adipocytes 148
Highly chiral muscarinic ligands: synthesis and affinity of diastereomeric and enantiomeric isomers of 1-methyl-2-(2-methyl-1,3-oxathiolane-5-yl)pyrrolidine 3-sulfoxides and their methyl iodides 140
Metodo per rimuovere un gruppo protettivo di un composto tetrazolico N-protetto 139
Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs 136
Design, synthesis and pharmacological evaluation of novel analogues of the two nootropics unifiram (DM232) and sunifiram (DM235) 135
synthesis, chiral HPLC separation and pharmacological characterization of muscarinic furan derivatives 134
Synthesis and pharmacological characterization of diastereomeric and enantiomeric isomers of 1-methyl-2-(2-methyl-1,3-oxathiolane-5-yl)pyrrolidine 3-sulfoxides and their methyl iodides 134
Rigid Analogs of DMPP As Probes For The Nicotinic Receptors 130
Synthesis and pharmacological evaluation of new nicotinic ligands carrying a quinoline nucleus 122
Molecular simplification of DM232 and DM235, two new potent cognition enhancers 119
Intermediate compounds for the preparation of angiotensin II antagonists 118
Sintesi chirale e valutazione farmacologica preliminare degli enantiomeri di DM232 e MC68, due azabiciclononanoni modulatori dei processi cognitivi 108
Progettazione, sintesi e valutazione farmacologica preliminare di analoghi strutturali di Sunifiram e Sapunifiram, due potemti agenti nootropi 96
Totale 7.840
Categoria #
all - tutte 20.427
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.427


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022266 0 0 30 5 9 18 23 11 10 13 73 74
2022/2023857 70 144 30 94 54 161 109 65 90 5 30 5
2023/2024308 11 30 46 13 17 57 9 85 5 6 10 19
2024/20252.042 55 212 126 280 649 348 13 124 54 57 64 60
2025/20261.970 245 280 134 107 240 93 246 68 126 112 38 281
2026/2027324 62 60 202 0 0 0 0 0 0 0 0 0
Totale 7.840